INCR - Incara Pharmaceuticals Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INCR - Incara Pharmaceuticals Corporation

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: JEB who wrote ()	7/22/1999 7:32:00 PM
From: JEB	of 13

The stock swap effectively reduces the outstanding shares to 3.1 Million. Also, reduces the investment still needed to finalize the phase III BEXTRA study to only 35% in the U.S. and Japan. INCR will share the costs and territory with BASF Pharma/Knoll AG (Germany) and will pay a royalty through CPEC to IPIC. biz.yahoo.com BTW - BEXTRA phase III completion is scheduled around June of 2000

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext